These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35793222)

  • 21. Alternative models and randomization techniques for Bayesian response-adaptive randomization with binary outcomes.
    Proper J; Connett J; Murray T
    Clin Trials; 2021 Aug; 18(4):417-426. PubMed ID: 33926267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian adaptive design approach for stepped-wedge cluster randomized trials.
    Wang J; Cao J; Ahn C; Zhang S
    Clin Trials; 2024 Aug; 21(4):440-450. PubMed ID: 38240270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
    Arjas E; Gasbarra D
    BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-stage randomized clinical trials with a right-censored endpoint: Comparison of frequentist and Bayesian adaptive designs.
    Boumendil L; Chevret S; Lévy V; Biard L
    Stat Med; 2024 Aug; 43(18):3364-3382. PubMed ID: 38844988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
    Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
    Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.
    Chen DT; Schell MJ; Fulp WJ; Pettersson F; Kim S; Gray JE; Haura EB
    Transl Cancer Res; 2019 Jul; 8(Suppl 4):S404-S420. PubMed ID: 31456910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covariate adjustment in Bayesian adaptive randomized controlled trials.
    Willard J; Golchi S; Moodie EE
    Stat Methods Med Res; 2024 Mar; 33(3):480-497. PubMed ID: 38327082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint.
    Qing Y; Thall PF; Yuan Y
    Pharm Stat; 2023 Jan; 22(1):34-44. PubMed ID: 35851545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian enhancement two-stage design with error control for phase II clinical trials.
    Jin H; Yin G
    Stat Med; 2020 Dec; 39(29):4452-4465. PubMed ID: 32854163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpreting a Bayesian phase II futility clinical trial.
    Beall J; Cassarly C; Martin R
    Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.